🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Camostat Mesilate

    United Therapeutics Europe Ltd

    Severe Acute Respiratory Syndrome

    phase 2 small molecule completed

    1 trial

  2. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adrenal Cortical Carcinoma

    phase 2 small molecule active

    1 trial

  3. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Cancer, Nonsmall Cell

    phase 2 small molecule active

    1 trial

  4. Camrelizumab

    The First People's Hospital of Lianyungang

    Locally Advanced or Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

  6. Camrelizumab

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 small molecule active

    1 trial

  7. Camrelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  8. Camrelizumab

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  9. Camrelizumab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  10. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  11. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  12. Camrelizumab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 other active

    1 trial

  13. Camrelizumab plus apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  14. Camrelizumab with vinorelbine and cisplatin

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Cangpo Liujun Prescription

    The First People's Hospital of Lianyungang

    Cancer-Related Fatigue

    phase 2 small molecule active

    1 trial

  16. Cannabidiol Capsules, Füllstoffmischung DAC in hardshell gelatine capsules, size 1, is used as placebo. Füllstoffmischung DAC consists of mannitol 99.5 % and silloidal silicon dioxide (Aerosil®) 0.5 %.

    The George Institute

    Remitted early phase schizophrenia

    phase 2 small molecule active

    1 trial

  17. Cannabidivarin

    Jazz Pharmaceuticals Ireland Limited

    Autism Spectrum Disorder

    phase 2 small molecule active

    1 trial

  18. Capecitabina KERN PHARMA 150 mg comprimidos recubiertos con película EFG, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Irinotecán Hospira 20 mg/mL concentrado para solución para perfusión EFG., Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Capecitabina

    The George Institute

    Localised Colon Cancer (stage II-III)

    phase 2 small molecule active

    1 trial

  19. Capecitabine

    The First People's Hospital of Lianyungang

    Biliary Carcinoma

    phase 2 small molecule active

    1 trial

  20. Capecitabine Accord 500 mg film-coated tablets

    Ningbo Cancer Hospital

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  21. Capecitabine+Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stomach Neoplasms

    phase 2 small molecule terminated

    1 trial

  22. Capecitabine-Oxaliplatin-Irinotecan Combination

    The First People's Hospital of Lianyungang

    Unresectable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  23. Carbon Nanoparticle Iron Suspension for Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HNSCC

    phase 2 small molecule active

    1 trial

  24. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etomedac 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung

    Ningbo Cancer Hospital

    Stage IIA/B seminoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources